Changes in carbohydrates on the cell surface are associated with tumor malignancy. The mucin-type core 2 b-1,6-N-acetylglucosaminyltransferase (C2GnT-M) is highly expressed in the gastrointestinal tract and catalyses the formation of core 2, core 4, and blood group I branches on O-glycans. In the present study, we evaluated the role of C2GnT-M in colorectal cancer. C2GnT-M downexpression was observed in 73.6% of the primary tumors from colorectal cancer patients (39 of 53) analysed by cancer profiling array. Consistently, the majority of colon cancer cell lines and primary colon tumors expressed lower levels of C2GnT-M than did normal colon tissues by RT-PCR. HCT116 cells stably transfected with C2GnT-M inhibited expression of the core 1 structure, Galb1,3GalNAca1-Ser/Thr, on the cell surface. Moreover, C2GnT-M expression suppressed cell adhesion, motility, and invasion as well as colony formation ability. The growth of C2GnT-M-transfected HCT116 and SW480 cells was dramatically suppressed, and the cell death induced by C2GnT-M was demonstrated by an increase in the annexin V-positive cells. Interestingly, C2GnT-M inhibited cell adhesion to collagen IV and fibronectin, and decreased tyrosine phosphorylation of paxillin, indicating that the changes in cancer behavior may be partly mediated by integrin-signaling pathways. Tumor growth in vivo was also significantly suppressed by C2GnT-M in the xenografts of nude mice. These results demonstrate that C2GnT-M is frequently downregulated in colorectal cancer and suppresses colon cancer cell growth.
Introduction
Cancer cells usually express specific carbohydrate epitopes on the cell surface. Several tumor-associated antigens have been identified on mucins (Springer, 1984; Cao et al., 1995; Fukuda, 1996; Baldus et al., 2000; Schneider et al., 2001; Hakomori, 2002) . Mucin-type glycoproteins are heavily glycosylated and are mainly decorated with complex O-glycans. Alterations in the Oglycosylation of mucins accompany the development of cancer and influence cell-cell and cell-extracellular interactions. These interactions regulate tumor growth, adhesion, invasion, metastasis, and immune surveillance (Hollingsworth and Swanson, 2004) . However, the glycosyltransferases that regulate the expression of these carbohydrate epitopes are still not well understood.
Mucins are highly expressed by epithelial cells in the gastrointestinal tract. The membrane-bound or secreted mucins constitute a heterogeneous group of glycoproteins with O-glycans. Core 2 branching is a key step in forming elongated O-glycans on mucins in various cell types. The core 2 b-1,6-N-acetylglucosaminyltransferase (C2GnT) transfers GlcNAc to GalNAc of the core 1 acceptor structure Galb1-3GalNAca-Ser/Thr to form the core 2 branch in b-1,6 linkage. To date, three members of C2GnT have been cloned, leukocyte-type C2GnT (C2GnT-L or C2GnT1) (Bierhuizen and Fukuda, 1992) , mucin-type C2GnT (C2GnT-M or C2GnT2) (Schwientek et al., 1999; Yeh et al., 1999) , and thymusassociated C2GnT (C2GnT-T, C2GnT3) (Schwientek et al., 2000) . In addition to the formation of the core 2 structure, C2GnT-M also exhibits activities to form the core 4 and I branch, as shown in Figure 1 (Schwientek et al., 1999; Yeh et al., 1999) . Although C2GnT-M is highly expressed in the gastrointestinal tract, its physiologic or pathologic function in the gastrointestinal tract has not yet been studied.
T antigen (core 1 structure) and its related carbohydrate antigens, such as Tn, T, and their sialylated variants, are oncofetal carbohydrate antigens (Springer, 1984; Cao et al., 1995; Fukuda, 1996; Brockhausen, 1998 Brockhausen, , 1999 Baldus et al., 2000; Schneider et al., 2001; Hakomori, 2002) . Changes in the expression of T antigen-related carbohydrates on cell surfaces have been observed in a variety of cancers (Hanisch and Baldus, 1997) . These carbohydrate structures have been correlated with cancer metastasis and prognosis (Cao et al., 1995; Baldus et al., 2000) . In addition, the interaction between T antigen and galactin-3 has been found to mediate cancer cell adhesion to endothelia (Khaldoyanidi et al., 2003) . Therefore, the T antigen has been targeted for the development of tumor vaccines (Springer, 1997) .
In the present study, we have examined the expression and role of C2GnT-M in colorectal cancer. The results indicate that C2GnT-M was expressed at low levels in the majority of colorectal carcinomas and colon cancer cell lines. Re-expression of C2GnT-M in the colon cancer cell line HCT116 caused round-up morphology, and decreased T antigen expression, as well as reduced cell migration, adhesion, and invasion. Moreover, expression of C2GnT-M dramatically inhibited cell growth and suppressed tumorigenicity in nude mice. These results suggest that C2GnT-M could suppress colorectal cancer growth both in vitro and in vivo.
Results

C2GnT-M is downregulated in human colorectal adenocarcinomas
To examine whether C2GnT-M expression is dysregulated in certain types of human cancer, we used a Cancer Profiling Array I (BD Biosciences). The DNA array contains pairs of cDNA generated from 13 different types of matched tumor/normal tissues, enabling the study of C2GnT-M expression in normal and tumor samples side by side. The amounts of C2GnT-M mRNA in 241 pairs of patient cDNA were quantified by densitometry and normalized to ubiquitin mRNA as described in the manufacturer's protocol. We observed that C2GnT-M was downregulated in the majority of colon and rectal tumors compared with their normal counterparts (Figure 2a ). Quantitative analysis indicated that 71.4% (25/35) of colon and 77.8% (14/18) of rectal tumors showed decreased expression of C2GnT-M (Figure 2b) . Moreover, the tumor/normal ratios of C2GnT-M o0.5 were 65.7 and 61.1% in colon and rectal tumors, respectively.
To analyse the C2GnT-M expression further, we performed PCR with a human colon matched cDNA pair panel (BD Biosciences) which consisted of cDNA pairs from five patients. Each pair was from an individual patient and was prepared from both the tumor and corresponding normal tissues. Consistent with the result from Cancer Profiling Array I, C2GnT-M expression was significantly decreased in tumor tissues compared with normal mucosa in all patients ( Figure 2c ). In contrast, b-actin expression was similar in all normal and matched tumor tissues. In addition, there was no significant difference in C2GnT-L expression levels between normal and cancerous colon tissues in these five patients. Our data suggest that downregulation of mucin-type C2GnT-M exhibited a good correlation with colorectal carcinomas.
To determine whether C2GnT-M expression was also downregulated in colorectal cancer cell lines HCT116, SW480, LoVo, and HT29, the C2GnT-M transcripts were analysed by RT-PCR with OneStep RT-PCR kit (Qiagen). Normal colon mRNAs (BD Biosciences) were used as a control. As shown in Figure 2d and e, the C2GnT-M expression was undetectable in SW480. The HCT116 and LoVo expressed lower levels of C2GnT-M than did normal colon tissues. However, the HT29 cells expressed C2GnT-M at high levels similar as normal colon tissues, which is consistent with previous reports (Vavasseur et al., 1995; Schwientek et al., 1999) . In contrast, the expression levels of C2GnT-L and b-actin mRNA in all four colon cancer cell lines were similar to that of normal colon tissues. These data further confirm that C2GnT-M mRNA was significantly downregulated in colorectal carcinomas.
C2GnT-M expression downregulates T antigen expression and causes carbohydrate changes on the cell surface To show whether C2GnT-M is able to regulate T antigen (core 1) expression, we stably transfected the HCT116 colon cancer cell line with either human C2GnT-M (HCT116/C2GnT-M) or control pcDNA3.1/myc-His vector (HCT116/mock) and then analysed the surface expression of T antigen by flow cytometry with FITCconjugated peanut agglutinin lectin (PNA), which can recognize T antigen. Three positive clones with C2GnT-M expression were screened by immunocytochemical staining with use of an anti-myc monoclonal antibody. Flow cytometry showed that C2GnT-M expression significantly decreased the PNA binding to 47% compared with the mock transfectants (Figure 3 ). These Figure 1 Enzyme activities of C2GnT-M. C2GnT-M exhibits enzyme activities of forming core 2, core 4, and blood group I branch.
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M-C Huang et al data suggest that C2GnT-M expression was able to downregulate T antigen expression in colon cancer. To investigate whether other surface carbohydrates could be affected by C2GnT-M in the presence of endogenous C2GnT-L, a panel of lectins Erythrina cristagalli (ECA), wheat germ agglutinin (WGA), Vicia villosa agglutinin (VVA), Wistaria floribunda (WFA), and phytohemagglutinin-L (PHA-L) as well as anti-I polyclonal antibody and anti-sialyl lewis X monoclonal antibody CSLEX-1 were used for flow cytometry. We found that C2GnT-M expression increased the binding of ECA and WGA, which recognize Gal(b1,4)GlcNAc as well as GlcNAc and sialic acid, respectively (Figure 3 ). In contrast, the binding of VVA, WFA, and PHA-L was Figure 2d were quantified and normalized to b-actin. *Po0.01 compared with normal colon tissues.
C2GnT-M in colorectal cancer M-C Huang et al weak and without significant changes. With respect to anti-I and CSLEX-1, no signals were detected on the surface of mock and C2GnT-M transfectants. These data suggested that in addition to T antigen, C2GnT-M was able to change other carbohydrates on the cell surface.
C2GnT-M inhibits cell spreading and cell adhesion We observed that all HCT116/C2GnT-M stable transfectants exhibited dramatic morphologic changes on cell culture plates after seeding cells for 24 h (Figure 4a ). Most cells of C2GnT-M stable transfectants showed round-up morphology. As shown in Figure 4b , the number of spread cells was only 873 per field for the C2GnT-M stable transfectants. However, 7373 cells per field exhibited spreading morphology for the mock transfectants. The spreading of C2GnT-M stable transfectants was observed after seeding for 48 h. Similar results were also found in all three C2GnT-M stable transfectants. These data demonstrated that C2GnT-M inhibited cell spreading and caused round-up morphology of colon cancer cells.
Cell adhesion to extracellular matrix is an initial step in tumor invasion. This adhesion is mediated through matrix proteins, such as collagen IV, fibronectin, or laminin. To elucidate the effect of C2GnT-M on tumor invasion further, we examined cell adhesiveness to collagen IV, fibronectin, or laminin under serum-free conditions. HCT116/mock transfectants showed strong adhesion to collagen IV and fibronectin in a dose-dependent manner, but not to laminin when compared with a BSA control (Figure 4c and d). In sharp contrast, HCT116/C2GnT-M transfectants did not exhibit significant adhesion to collagen IV or fibronectin. These results showed that C2GnT-M played 
M-C Huang et al a role in reducing colon cancer cell adhesion to collagen IV and fibronectin.
C2GnT-M inhibits cell migration and invasion
The effect of C2GnT-M on cell migration was assessed by a monolayer wound-healing assay. For this analysis, cultures of confluent contact-inhibited cells grown on 12-well culture dishes were scratched with a 250-ml pipette tip to create a denuded area, and then the cells at the wound edges were allowed to migrate into the denuded area over a 36 h period. After 36 h, the scraped area of HCT116/mock, but not HCT116/C2GnT-M, transfectants was closed ( Figure 5a ). The migration velocities of the mock and C2GnT-M transfectants were 24.64 and 9.28 mm, respectively. It is evident that the cells expressing C2GnT-M migrated into the wound area more slowly than did the cells expressing the vector alone. These data showed that C2GnT-M decreased the cell motility of colon cancer cells.
Tumor cell invasion is a critical process in cancer metastasis. Tumor invasion involves cell attachment to the extracellular matrix (ECM), localized degradation of the ECM, and cell migration through the tissue barrier (Liotta and Stetler-Stevenson, 1991) . To investigate the role of C2GnT-M in the invasion of colorectal cancer, we performed a matrigel invasion assay, which mimics active transmigration of tumor cells across a reconstituted basement membrane. The invading numbers of HCT116 cells stably expressing C2GnT-M were only 171 per field (Figure 5b) . In sharp contrast, 3979 cells/ field was observed in mock transfectants. These data showed that C2GnT-M expression resulted in almost complete inhibition of invasion as determined by the matrigel invasion assay.
Since FAK (focal adhesion kinase) and paxillin are important signaling molecules downstream of ECMintegrin interactions, we analysed whether tyrosine phosphorylation of FAK and paxillin is affected by C2GnT-M expression. As shown in Figure 5c , the amount of pY397 FAK was only slightly, if any, decreased in the C2GnT-M-transfected cells compared with mock-transfected cells. Interestingly, the expression levels of pY118 paxillin were markedly decreased. In contrast, the protein levels of total FAK and paxillin did not show any significant changes. These data strongly suggest that the C2GnT-M overexpression suppressed integrin-mediated signaling pathways.
C2GnT-M suppresses cell growth and induces apoptotic cell death To examine the effect of C2GnT-M expression on growth regulation, we counted the cell number of mock and C2GnT-M stable transfectants in a monolayer culture every 24 h to determine the cell growth rate. To know whether the effects of C2GnT-M on cell growth and apoptosis are restricted to the HCT116 cell line, we analysed another colon cancer cell line SW480 in addition to HCT116 cells. By day 4, we observed that the cell growth of C2GnT-M transfectants of SW480 and HCT116 cells was suppressed by about 50-70% compared with their corresponding mock-transfected cells (Figure 6a ). These data showed that C2GnT-M dramatically inhibited the cell growth of colon cancer cells in vitro.
To analyse whether the reduced cell growth is due to an increase in cell death, we performed flow cytometry with FITC-labeled annexin V at different time points as shown in Figure 6b . At day 0, the same numbers of cells were seeded and the cell viability was confirmed to be >95% by trypan blue exclusion assays. We found that at day 0 and day 1 after seeding the cells, the percentage of annexin V-positive cells of C2GnT-M stable transfectants was similar to that of mock transfectants. At day 2, C2GnT-M stable transfectants of SW480 and HCT116 showed 15% and 13% annexin V-positive cells, respectively. In contrast, only 4% annexin V-positive cells were found in mock transfectants. These data indicate that the expression of C2GnT-M leads to an apoptotic cell death in colon cancer cells. In addition, C2GnT-M in colorectal cancer M-C Huang et al DNA fragmentation assays also showed that the C2GnT-M did induce apoptotic DNA fragmentation (data not shown).
C2GnT-M inhibits colony-forming ability of colon cancer cells It is well established that the colony formation assay is predictive of tumorigenicity in vivo. The stable transfectants were subjected to soft-agar growth assay, and colony formation was determined. We found that stable transfection of C2GnT-M inhibited the colonyformation ability of HCT116 and SW480 cells by 97 and 90% compared with their mock transfectants, respectively, (Figure 7a and b) . In addition, the average colony size of C2GnT-M transfectants is much smaller than that of the mock transfectants (data not shown). These results indicated that expression of C2GnT-M leads to a strong decrease in the capability of HCT116 cells for anchorage-independent growth and may inhibit the tumorigenic phenotype.
C2GnT-M suppresses tumor growth in vivo The effect of the C2GnT-M gene on tumor growth in vivo was evaluated by subcutaneous injection of C2GnT-M stable transfectants into BALB/c nude mice. Six nude mice for mock or C2GnT-M stable transfectants were examined. Tumor growth was monitored, and mice were killed for measurement of tumor weight at 20 days inoculation. The mock transfectants formed much larger tumors than did C2GnT-M transfectants within a short time period, as shown in Figure 8a . The C2GnT-Mexpressing xenografts exhibited significant suppression of tumor weight, reaching only 13% of that of the control tumors by day 20 (Figure 8c ). Two mice xenografted with C2GnT-M transfectants did not show tumor growth when they were killed (Figure 8b ). These data indicate that the expression of C2GnT-M in HCT116 cells resulted in a significant suppression of tumor growth.
Discussion
The frequent occurrence of short O-glycans is a common feature of various cancers. Several studies have demonstrated a correlation of T antigen (core 1 structure) expression with malignancy. An immunohistochemical study of 264 patients showed that T antigen expression is an independent prognostic factor for lower survival probability in colorectal carcinoma (Baldus et al., 2000) . However, the glycosyltransferases responsible for changes in core 1 expression are still not well understood. In the present study, we showed that C2GnT-M expression was expressed at low levels in the majority of colorectal carcinomas and colon cancer cell lines compared with normal colon tissues. By using a cancer profiling array, we found that C2GnT-M was highly expressed in the normal gastrointestinal tract, for example, colon, rectum, and stomach, which was also found in a previous report (Yeh et al., 1999) . Interestingly, there was no significant difference in C2GnT-M 
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M-C Huang et al expression between the normal and cancerous stomach. To further confirm C2GnT-M expression is downregulated, we used the paired cDNAs from five colorectal cancer patients (BD Sciences) and four colon cancer cell lines for PCR and RT-PCR analysis. All tested patients and colon cancer cell lines showed downregulation of C2GnT-M expression. Shimodaira et al. (1997) reported that C2GnT-L transcripts were specifically detected in colorectal cancer tissues of 63% of patients, and the expression levels were correlated with vessel invasion and depth of tumor invasion. In consistent with their finding, the C2GnT-L was easily detected in colorectal cancerous tissues and cell lines, although the difference between the expression levels of normal and cancerous tissues or cell lines is not evident. We also observed that the downregulation of C2GnT-M in patients or expression levels of C2GnT-M in cell lines are not correlated with the expression levels of C2GnT-L. Our results suggest that the C2GnT-M expression is independent of the C2GnT-L expression, and is frequently downregulated in colorectal cancer.
We showed that C2GnT-M significantly inhibited core 1 expression on the cell surface of HCT116, suggesting that C2GnT-M downregulation in colorectal cancer may lead to an increase in core 1 expression. It has been found consistently that the enzyme activity needed to synthesize core 2, core 4, and the I branch was decreased in homogenates prepared from colon tumors . Moreover, the expression of core 4-and I branch-synthesizing enzymes was turned off during progression toward adenocarcinoma (Vavasseur et al., 1994) . These data support that the C2GnT-M was decreased in colorectal carcinomas. Thus, the downregulation of C2GnT-M could be one of the important factors responsible for core 1 (T antigen) overexpression in colorectal cancer.
It has been found that C2GnT-L was able to inhibit T antigen (core 1) expression in SW480 cells (Schneider et al., 2001) . By stable transfection of HCT116 cells, we found that C2GnT-M also decreased the core 1 structure, suggesting that this could be due to the processing of the core 1 structure (T antigen) to core 2 through C2GnT activity of C2GnT-M. Core 3 synthase was found to be significantly downregulated in colon cancer (Iwai et al., 2005) . In addition, we could not detect I antigen expression on mock and C2GnT-M transfectants of HCT116. These data suggest that the main enzyme activity of C2GnT-M in colon cancer cells could be to generate the core 2, but not core 4 and I branches. Thus, C2GnT-M and C2GnT-L may have similar functions in colon cancer cells. Interestingly, our data showed that the C2GnT-M increased ECA and WGA binding, suggesting that C2GnT-M can make several changes in surface carbohydrates even in the presence of endogenous C2GnT-L expression.
Integrins are the main cell-surface receptors for ECM proteins, such as collagen, laminin, and fibronectin. Cell-ECM interactions cause reorganization of cytoskeletons at focal contacts and regulate various signaling pathways which are involved not only in cell adhesion and migration but also in cell growth, apoptosis, and differentiation (Hynes, 2002; Guo and Giancotti, 2004) . Here, we have observed that cell adhesion to collagen IV and fibronectin as well as invasion in matrigel were markedly inhibited in C2GnT-M-transfected cells. Moreover, tyrosine phosphorylation of paxillin Y118 was significantly suppressed by C2GnT-M. Paxillin, a 70-kDa protein localized to focal adhesions (Turner et al., 1990) , was phosphorylated in response to integrinmediated adhesion (Burridge et al., 1992) . Several reports have indicated that tyrosine phosphorylation of paxillin regulates cell adhesion, migration, and invasion (Bowden et al., 1999; Petit et al., 2000; Tsubouchi et al., 2002; Lamorte et al., 2003) . These data strongly suggest that these effects could be mainly mediated via integrin-mediated signaling. One of the C2GnT-M in colorectal cancer M-C Huang et al simplest explanations for these effects is that C2GnT-M modifies O-glycans on membrane-bound and secreted mucins, which, in turn, affects integrin signaling by physically hampering integrin-ECM interactions. Second, certain mucins can directly interact and regulate integrin activity. C2GnT-M alters the O-glycans on these mucins and then affects the integrin-mucin interactions, which in turn block integrin-ECM interactions. Third, certain integrins are directly modified by C2GnT-M, and which, in turn, blocks the integrin signaling and leads to changes in various cell behaviors.
Interestingly, it was recently found that overexpression of a2,6-sialyltransferase ST6GalNAc I in murine mammary adenocarcinoma cells led to a major change in the O-glycosylation of b1 integrin, which, in turn, impaired integrin-mediated signaling and altered cell morphology, motility, and proliferation (Clement et al., 2004) . It was suggested that the potential O-glycosylation region of b1 integrin is the STT motif localized within the I-like domain, and that the STT motif is present in both murine and human b1 integrin. Therefore, it will be of great interest to analyse whether C2GnT-M can modify integrin(s) and regulate the integrin signaling in colorectal carcinoma. Although the third mechanism is the one we favor, we still cannot rule out the possibility that C2GnT-M exerts its function via the first two or other non-integrin-mediated mechanisms.
The changes in morphology and various cancer phenotypes caused by C2GnT-M were not artefacts, because all C2GnT-M-expressing clones showed similar altered morphology and reduced cell adhesion and proliferation. In contrast, we did not observe any significant changes in phenotypes between mock transfectants and HCT116 parental cells. To know the C2GnT-M effects on colon cancer cells are not restricted to HCT116 cell line, we also tested some growth-related effects of C2GnT-M on another colon cancer cell line SW480. We did observe a similar growth-inhibitory and apoptotic effect of C2GnT-M on SW480 cells in addition to HCT116 cells.
We found that C2GnT-M not only inhibited cell growth in vitro and in vivo but also suppressed migration and invasion. Several studies have shown that glycosyltransferases can modulate tumor growth and progression. Gene transfer of a1,3-fucosyltransferase increased tumor growth of the PC-3 human prostate cancer cell line (Inaba et al., 2003) . Interestingly, mutations of exostosin-1 and exostosin-2 were found to be the cause of hereditary multiple exostoses, and these two genes belong to a novel family of tumor suppressor genes which encode glycosyltransferases with the activity of polymerizing heparan sulfate (Duncan et al., 2001 ). An aberrant glycosylation of cell-surface receptors has been found to result in dysfunctional intracellular signaling and altered cellular behaviors. Defective angiogenesis and fatal embryonic hemorrhage were recently discovered in mice lacking b1,3-galactosyltransferase (C1Gal-T1) (Xia et al., 2004) . ST6GalNAc I expression was shown to decorate b1 integrin with sialyl-Tn and led to an altered morphology, impaired proliferation, and decreased migration in colon carcinoma cells (Clement et al., 2004) . Our results support the theory that differential expression of glycosyltransferases could be one of the important factors regulating tumor growth and progression. We found that C2GnT-M was highly expressed in normal colon tissues. However, its expression diminished growth and adhesion of colon cancer cells. This raises a question whether C2GnT-M expression affects the viability of primary epithelial cells in the gastrointestinal tract. We assume that deregulation of a variety of genes in cancer cells makes the changes caused by C2GnT-M expression become deleterious. In contrast, the surface carbohydrates and signals affected by C2GnT-M are tightly regulated and exert their biological functions without toxic effects.
In conclusion, we have found decreased expression of C2GnT-M in colorectal cancer. Re-expression of C2GnT-M in colon cancer cells significantly altered a variety of cancer properties, including morphology, adhesiveness, migration, invasion, colony formation ability, and cell growth. The suppressive activity of C2GnT-M in tumor growth in vitro and in vivo strongly suggested that alterations of the O-glycan structure are involved in tumorigenesis. This study demonstrates that C2GnT-M is able to regulate a wide range of cellular activities that are important for carcinogenesis. It will be interesting to elucidate further the underlying mechanism by which C2GnT-M suppresses tumorigenesis and to apply this information to cancer gene therapy.
Materials and methods
Cancer profiling array
Cancer profiling array I (BD Biosciences Clontech), containing normalized cDNA from 241 tumor and corresponding normal tissues, was used for detecting the differential expression of C2GnT-M. The 32 P-labeled cDNA fragments corresponding to amino acid 1-116 of C2GnT-M, which covers a highly diversified region of the C2GnT family, were used for probing of the filter. The C2GnT-M signals obtained were quantified by densitometer and normalized to ubiquitin signals as suggested in the manufacturer's instructions.
Semiquantitative RT-PCR Total cellular RNAs were isolated from cells grown to 70% confluence by use of the Trizol reagent (Invitrogen, Life Technologies, Inc.) according to the manufacturer's protocol. For cDNA synthesis, 1 mg of total RNA was used as template in a 20 ml RT reaction. Alternatively, matched cDNA pairs of colon cancer patients (BD Biosciences Clontech) were used for PCR. To reflect the initial mRNA expression levels, PCR amplification of cDNA was carried out with cycle numbers that have been tested to be in the linear range, as previously described (Huang et al., 2002) . PCR reactions were performed in a final volume of 50 ml with 2.5 U of Taq polymerase (GenTaq, Taiwan), and 2 ml of ss cDNA from RT reaction or 5 ml of matched cDNAs (BD Biosciences Clontech) as templates. The PCR amplification was carried out in an ASTEC (PC320) thermal cycler: 951C for 5 min, followed by 35 cycles of 941C for 50 s, 561C for 50 s, and 721C for 50 s and by a single incubation at 721C for 10 min. Qiagen OneStep RT-PCR kit was used for RT-PCR in some experiments according to the manufacturer's protocol. PCR products were separated by 1.5% agarose (Sigma) gel electrophoresis. The images were quantified with an image analysing software (EZ lab, Taiwan).
Construction of plasmids
RT-PCR was performed for cloning of full-length human C2GnT-M (AF-102542) from normal colon total RNA (BD Biosciences Clontech). The sense primer was 5 0 -CGG AATTCGACGATGGTTCAATGGAA-3 0 , and the antisense primer was 5 0 -GCTCTAGAGCCAAGTTCAGTCCCAT-3 0 . The RT-PCR products were cloned into pcDNA3.1/myc-His (InVitrogen Life Technologies, Inc.) to generate the C2GnT-M/myc-His fusion gene. The insert was confirmed by DNA sequencing.
Cell culture and transfection HCT116, SW480, and LoVo were purchased from CCRC (Hsinchu, Taiwan) and HT29 (ATCC) were maintained with Dulbecco's modified Eagle's medium (DMEM) (Biowest) containing 10% fetal bovine serum (FBS) (Biowest) in humidified tissue culture incubator at 371C, in a 5% CO 2 atmosphere. In total, 4 mg of C2GnT-M/pcDNA3.1/myc-His or pcDNA3.1/myc-His were transfected into 5 Â 10 5 HCT116 or SW480 cells by use of Lipofectamine 2000 (InVitrogen). After 24 h of transfection, the cells were trypsinized and plated on three 100-mm dishes with 10% FBS-DMEM containing 600 mg/ml of G418 (Calbiochem). After 2 weeks of selection, G418-resistant clones were isolated and transferred to 24-well plates. The positive clones and the expression levels of C2GnT-M were confirmed by use of RT-PCR and immunocytochemistry with anti-myc (9E10 clone) monoclonal antibodies.
Western blot HCT116 cells were transfected with either pcDNA3.1/myc-His or pcDNA3.1/C2GnT-M-myc-His. Equal amounts of cell lysate were electrophoresed on an SDS-PAGE and transferred to a nitrocellulose membrane. The membranes were incubated with anti-phospho-FAK (Tyr 397) polyclonal antibody (Bioresources), anti-FAK polyclonal antibody (C-20, Santa Cruz), anti-phospho-paxillin (Tyr 118) (Transduction lab), antipaxillin polyclonal antibody (Transduction lab), and then incubated with HRP-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology, CA, USA). For detection of C2GnT-Mmyc-His expression, anti-myc or 4G10, and goat anti-mouse IgG (SouthernBiotech) were used. The signals were visualized with ECL reagents (Amersham Biosciences).
Lectin and antibody binding
To detect changes of surface carbohydrates, cells were stained with a panel of lectins and anti-carbohydrate antibodies and then analysed with a flow cytometer. FITC-labeled PNA was purchased from Merck Biosciences. TRITC-labeled ECA, WGA, VVA, WFA, and PHA-L were from EY laboratories. The anti-I plolyclonal antibody and anti-sialyl Lewis X monoclonal antibody CSLEX-1 were from DiaMed AG and BD Biosciences, respectively.
Apoptosis and flow cytometry
The C2GnT-M stable transfectants and mock transfectants were trypsinized and washed once with PBS. For apoptosis analysis, FITC-annexin V (SouthernBiotech) was used to stain cells for 20 min on ice and annexin V-positive cells were analysed with flow cytometer (BD Biosciences).
Morphology
Cells were grown on 100-mm culture plates (Falcon). After seeding for 24 h, cells were observed and photographed under an inverted phase-contrast microscope. Spreading cells were calculated at five different fields and are presented as mean values7s.d.
Cell adhesion assay A cell adhesion assay was performed according to published protocols (Quattrocchi et al., 2002) with modifications. Ninety-six-well plates were coated overnight with human collagen IV (Sigma), human fibronectin (Sigma), murine laminin (Sigma), or bovine serum albumin (BSA) (Sigma) at concentrations of 1 or 5 mg/ml in PBS, pH 7.4, and then blocked with 1% BSA in PBS at 371C for 2 h. Cells were harvested, washed with serum-free DMEM, and then recovered in serum-free DMEM at 371C for 40 min. Mock and C2GnT-M stable transfectants (2 Â 10 4 in 100 ml/well) were allowed to attach for 1 h at 371C in a humidified 5% CO 2 incubator. Unattached cells were removed with PBS. Attached cells from five wells were counted manually under an inverted microscope. All data are expressed as mean values7s.d.
Wound healing assays
Cells were seeded in 12-well culture dishes and grown until confluence in DMEM supplemented with 10% FBS. The monolayer was scratched with a sterile 250 ml pipette tip. The migration of cells to the cleared area was inspected under a microscope. Pictures were taken directly at the time of scratching and after scratching at 6 h intervals. Migration velocity is presented as migration distance (mm)/time (h).
Matrigel invasion assays A cell invasion assay was analysed in a BioCoatt Matrigelt Invasion Chamber (Becton-Dickinson, Bedford, MA, USA) according to the protocol provided by the manufacturer. Briefly, 2 Â 10 5 cells in 500 ml DMEM were added to each chamber and allowed to invade the matrigel for 48 h in a humidified tissue culture incubator at 371C, 5% CO 2 atmosphere. The non-invading cells on the upper surface of the membrane were removed from the chamber, and the invading cells on the lower surface of the membrane were fixed with 100% methanol and then stained with 0.5% crystal violet (Sigma). After two washes with distilled water, the chambers were allowed to air dry. The number of invading cells per field was counted under a phase contrast microscope. The mean values7s.d. were calculated from the numbers of five different fields under the microscope.
Cell growth analysis 4 Â 10counts were used for plotting of the relative growth rate with standard error.
DNA extraction and analysis of DNA fragmentation Soluble DNA was extracted as described previously (Steiner et al., 2000) , with slight modifications. Briefly, the suspended cells in medium were collected 48 h after seeding to 100-mm plates. The cell pellet was lysed in 10 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.5% Triton X-100 on ice for 15 min. The lysate was centrifuged at 12 000 g for 15 min to separate soluble (fragmented) DNA from pelleted (intact genomic) DNA. Soluble DNA was treated with 50 mg/ml RNase A at 371C for 1 h, followed by 100 mg/ml proteinase K (Promega) in 0.5% SDS at 501C for 2 h. The DNA was extracted with phenol/ chloroform once, precipitated with 1/10 V sodium acetate at À201C overnight, and electrophoresed on a 2% agarose gel.
Anchorage-independent growth in soft agar 1 Â 10 4 cells in 0.3% Bactoagar (Sigma) in DMEM supplemented with 10% FBS were overlaid on a base of 0.6% Bactoagar in DMEM supplemented with 10% FBS in 100-mm dishes. Cells were incubated at 371C, 5% CO 2 atmosphere. The number of colonies with diameter greater than 125 mm was counted at the end of 3 weeks.
Tumor growth in nude mice
For tumorigenicity assay in vivo, 8 Â 10 6 of mock or C2GnT-M stable transfectants of HCT116 in 100 ml PBS were injected subcutaneously into 6-week-old female BALB/c nude mice. Cells from each clone were injected into six mice. Tumor volumes were measured with electronic calipers and calculated by the following formula: volume ¼ 0.4 Â A Â B 2 , where A is the larger and B is the smaller axis (Ovadia et al., 1975) .
Abbreviations
RT-PCR, reverse -transcription-polymerase chain reaction; C2GnT, core 2 b-1,6-N-acetylglucosaminyltransferase; C4GnT, core 4 b-1,6-N-acetylglucosaminyltransferase; FAK, focal adhesion kinase; ST6GalNAc I, CMP, sialic acid:Gal b1,3GalNAc-R a6-sialyltransferase I.
